Karyopharm Therapeutics Inc. Payments to Acquire Debt Securities, Available-for-sale
Karyopharm Therapeutics Inc. (KPTI) reported Payments to Acquire Debt Securities, Available-for-sale of $10.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-13
- Karyopharm Therapeutics Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Karyopharm Therapeutics Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Karyopharm Therapeutics Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Karyopharm Therapeutics Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Karyopharm Therapeutics Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Karyopharm Therapeutics Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $58.82M, a 63.04% decline from fiscal 2023.
- Karyopharm Therapeutics Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $159.15M, a 29.58% decline from fiscal 2022.
- Karyopharm Therapeutics Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $226.02M, a 399.73% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.04M 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $0.00 derived: sum of 2 quarters · filed 2026-02-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 10-K · filed 2026-02-13 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $0.00 10-Q · filed 2025-11-03 | $1.51M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $1.51M derived: sum of 3 quarters · filed 2026-08-13 | $22.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 | $1.51M derived: sum of 2 quarters · filed 2026-02-13 | $22.31M derived: sum of 3 quarters · filed 2026-02-13 | $27.21M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $22.31M derived: sum of 2 quarters · filed 2026-02-13 | $27.21M derived: sum of 3 quarters · filed 2026-02-13 | $58.82M 10-K · filed 2026-02-13 |
| 2024-09-30 | $20.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $25.71M derived: sum of 2 quarters · filed 2025-11-03 | $57.32M 10-Q · filed 2025-11-03 | $73.88M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $4.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $36.51M 10-Q · filed 2025-08-11 | $53.07M derived: sum of 3 quarters · filed 2026-02-13 | $99.14M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $31.61M 10-Q · filed 2025-05-12 | $48.17M derived: sum of 2 quarters · filed 2026-02-13 | $94.23M derived: sum of 3 quarters · filed 2026-02-13 | $130.43M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $16.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $62.63M derived: sum of 2 quarters · filed 2026-02-13 | $98.82M derived: sum of 3 quarters · filed 2026-02-13 | $159.15M 10-K · filed 2026-02-13 |
| 2023-09-30 | $46.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $82.26M derived: sum of 2 quarters · filed 2024-11-05 | $142.59M 10-Q · filed 2024-11-05 | $239.69M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $36.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $96.53M 10-Q · filed 2024-08-06 | $193.62M derived: sum of 3 quarters · filed 2025-02-19 | $223.52M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $60.33M 10-Q · filed 2024-05-08 | $157.43M derived: sum of 2 quarters · filed 2025-02-19 | $187.33M derived: sum of 3 quarters · filed 2025-02-19 | $250.81M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $97.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $127.00M derived: sum of 2 quarters · filed 2025-02-19 | $190.48M derived: sum of 3 quarters · filed 2025-02-19 | $226.02M 10-K · filed 2025-02-19 |
| 2022-09-30 | $29.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $93.38M derived: sum of 2 quarters · filed 2023-11-02 | $128.92M 10-Q · filed 2023-11-02 | $128.92M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $63.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $99.02M 10-Q · filed 2023-08-02 | $99.02M derived: sum of 3 quarters · filed 2024-02-29 | $109.52M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $35.54M 10-Q · filed 2023-05-04 | $35.54M derived: sum of 2 quarters · filed 2024-02-29 | $46.04M derived: sum of 3 quarters · filed 2024-02-29 | $55.00M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $10.50M derived: sum of 2 quarters · filed 2024-02-29 | $19.46M derived: sum of 3 quarters · filed 2024-02-29 | $45.23M 10-K · filed 2024-02-29 |
| 2021-09-30 | $10.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $19.46M derived: sum of 2 quarters · filed 2022-11-03 | $45.23M 10-Q · filed 2022-11-03 | $71.89M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $8.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $34.73M 10-Q · filed 2022-08-04 | $61.40M derived: sum of 3 quarters · filed 2023-02-17 | $103.54M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $25.76M 10-Q · filed 2022-05-05 | $52.43M derived: sum of 2 quarters · filed 2023-02-17 | $94.57M derived: sum of 3 quarters · filed 2023-02-17 | $206.46M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $26.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $68.80M derived: sum of 2 quarters · filed 2023-02-17 | $180.69M derived: sum of 3 quarters · filed 2023-02-17 | $274.58M 10-K · filed 2023-02-17 |
| 2020-09-30 | $42.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $154.03M derived: sum of 2 quarters · filed 2021-11-03 | $247.91M 10-Q · filed 2021-11-03 | $336.07M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $111.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $205.77M 10-Q · filed 2021-08-05 | $293.93M derived: sum of 3 quarters · filed 2022-03-01 | $337.59M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $93.88M 10-Q · filed 2021-05-04 | $182.04M derived: sum of 2 quarters · filed 2022-03-01 | $225.70M derived: sum of 3 quarters · filed 2022-03-01 | $244.38M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $88.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $131.82M derived: sum of 2 quarters · filed 2022-03-01 | $150.50M derived: sum of 3 quarters · filed 2022-03-01 | $178.49M 10-K · filed 2022-03-01 |
| 2019-09-30 | $43.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $62.34M derived: sum of 2 quarters · filed 2020-11-02 | $90.33M 10-Q · filed 2020-11-02 | $235.48M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $18.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $46.67M 10-Q · filed 2020-08-04 | $191.82M derived: sum of 3 quarters · filed 2021-02-24 | $214.54M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $27.99M 10-Q · filed 2020-05-05 | $173.14M derived: sum of 2 quarters · filed 2021-02-24 | $195.86M derived: sum of 3 quarters · filed 2021-02-24 | $246.07M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $145.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $167.87M derived: sum of 2 quarters · filed 2021-02-24 | $218.07M derived: sum of 3 quarters · filed 2021-02-24 | $242.81M 10-K · filed 2021-02-24 |
| 2018-09-30 | $22.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $72.93M derived: sum of 2 quarters · filed 2019-11-04 | $97.66M 10-Q · filed 2019-11-04 | $122.02M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $50.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $74.94M 10-Q · filed 2019-08-07 | $99.30M derived: sum of 3 quarters · filed 2020-02-26 | $111.75M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $24.74M 10-Q · filed 2019-05-09 | $49.09M derived: sum of 2 quarters · filed 2020-02-26 | $61.55M derived: sum of 3 quarters · filed 2020-02-26 | |
| 2017-12-31 | $24.36M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $36.81M derived: sum of 2 quarters · filed 2020-02-26 | $98.37M 10-K · filed 2020-02-26 | |
| 2017-09-30 | $12.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $74.02M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $61.56M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $134.70M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |